143 related articles for article (PubMed ID: 16497833)
1. Reversal to cisplatin sensitivity in recurrent human ovarian cancer cells by NCX-4016, a nitro derivative of aspirin.
Bratasz A; Weir NM; Parinandi NL; Zweier JL; Sridhar R; Ignarro LJ; Kuppusamy P
Proc Natl Acad Sci U S A; 2006 Mar; 103(10):3914-9. PubMed ID: 16497833
[TBL] [Abstract][Full Text] [Related]
2. NCX-4040, a nitric oxide-releasing aspirin, sensitizes drug-resistant human ovarian xenograft tumors to cisplatin by depletion of cellular thiols.
Bratasz A; Selvendiran K; Wasowicz T; Bobko A; Khramtsov VV; Ignarro LJ; Kuppusamy P
J Transl Med; 2008 Feb; 6():9. PubMed ID: 18302761
[TBL] [Abstract][Full Text] [Related]
3. NCX-4016, a nitro-derivative of aspirin, inhibits EGFR and STAT3 signaling and modulates Bcl-2 proteins in cisplatin-resistant human ovarian cancer cells and xenografts.
Selvendiran K; Bratasz A; Tong L; Ignarro LJ; Kuppusamy P
Cell Cycle; 2008 Jan; 7(1):81-8. PubMed ID: 18196976
[TBL] [Abstract][Full Text] [Related]
4. Cooperation between aspirin-triggered lipoxin and nitric oxide (NO) mediates antiadhesive properties of 2-(Acetyloxy)benzoic acid 3-(nitrooxymethyl)phenyl ester (NCX-4016) (NO-aspirin) on neutrophil-endothelial cell adherence.
Fiorucci S; Distrutti E; Mencarelli A; Rizzo G; Lorenzo AR; Baldoni M; Del Soldato P; Morelli A; Wallace JL
J Pharmacol Exp Ther; 2004 Jun; 309(3):1174-82. PubMed ID: 14762100
[TBL] [Abstract][Full Text] [Related]
5. Nitroaspirin (NCX-4016), an NO donor, is antiangiogenic through induction of loss of redox-dependent viability and cytoskeletal reorganization in endothelial cells.
Parinandi NL; Sharma A; Eubank TD; Kaufman BF; Kutala VK; Marsh CB; Ignarro LJ; Kuppusamy P
Antioxid Redox Signal; 2007 Nov; 9(11):1837-49. PubMed ID: 17760507
[TBL] [Abstract][Full Text] [Related]
6. Molecular characterization of cytotoxic and resistance mechanisms induced by NCX 4040, a novel NO-NSAID, in pancreatic cancer cell lines.
Rosetti M; Tesei A; Ulivi P; Fabbri F; Vannini I; Brigliadori G; Amadori D; Bolla M; Zoli W
Apoptosis; 2006 Aug; 11(8):1321-30. PubMed ID: 16699954
[TBL] [Abstract][Full Text] [Related]
7. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
8. NCX 4040, a nitric oxide-donating aspirin, exerts anti-inflammatory effects through inhibition of I kappa B-alpha degradation in human monocytes.
Ricciotti E; Dovizio M; Di Francesco L; Anzellotti P; Salvatore T; Di Francesco A; Sciulli MG; Pistritto G; Monopoli A; Patrignani P
J Immunol; 2010 Feb; 184(4):2140-7. PubMed ID: 20065114
[TBL] [Abstract][Full Text] [Related]
9. Nitric oxide donating nonsteroidal anti-inflammatory drugs induce apoptosis in human prostate cancer cell systems and human prostatic stroma via caspase-3.
Royle JS; Ross JA; Ansell I; Bollina P; Tulloch DN; Habib FK
J Urol; 2004 Jul; 172(1):338-44. PubMed ID: 15201807
[TBL] [Abstract][Full Text] [Related]
10. Pharmacologic profile and therapeutic potential of NCX 4016, a nitric oxide-releasing aspirin, for cardiovascular disorders.
Gresele P; Momi S
Cardiovasc Drug Rev; 2006; 24(2):148-68. PubMed ID: 16961726
[TBL] [Abstract][Full Text] [Related]
11. Antioxidant activity of nitro derivative of aspirin against ischemia-reperfusion in hamster cheek pouch microcirculation.
Bertuglia S; Giusti A; Del Soldato P
Am J Physiol Gastrointest Liver Physiol; 2004 Mar; 286(3):G437-43. PubMed ID: 14563672
[TBL] [Abstract][Full Text] [Related]
12. Annexin XI is associated with cisplatin resistance and related to tumor recurrence in ovarian cancer patients.
Song J; Shih IeM; Salani R; Chan DW; Zhang Z
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6842-9. PubMed ID: 17982121
[TBL] [Abstract][Full Text] [Related]
13. NCX 4040, an NO-donating acetylsalicylic acid derivative: efficacy and mechanisms of action in cancer cells.
Tesei A; Zoli W; Fabbri F; Leonetti C; Rosetti M; Bolla M; Amadori D; Silvestrini R
Nitric Oxide; 2008 Sep; 19(2):225-36. PubMed ID: 18472019
[TBL] [Abstract][Full Text] [Related]
14. Pro-apoptotic effect of a nitric oxide-donating NSAID, NCX 4040, on bladder carcinoma cells.
Fabbri F; Brigliadori G; Ulivi P; Tesei A; Vannini I; Rosetti M; Bravaccini S; Amadori D; Bolla M; Zoli W
Apoptosis; 2005 Oct; 10(5):1095-103. PubMed ID: 16151642
[TBL] [Abstract][Full Text] [Related]
15. Effects of aspirin and NO-aspirin (NCX 4016) on platelet function and coagulation in human endotoxemia.
Derhaschnig U; Schweeger-Exeli I; Marsik C; Cardona F; Minuz P; Jilma B
Platelets; 2010; 21(5):320-8. PubMed ID: 20608787
[TBL] [Abstract][Full Text] [Related]
16. Nitric oxide release and distribution following oral and intraperitoneal administration of nitroaspirin (NCX 4016) in the rat.
Carini M; Aldini G; Orioli M; Piccoli A; Rossoni G; Maffei Facino R
Life Sci; 2004 May; 74(26):3291-305. PubMed ID: 15094329
[TBL] [Abstract][Full Text] [Related]
17. Nitric oxide regulates immune cell bioenergetic: a mechanism to understand immunomodulatory functions of nitric oxide-releasing anti-inflammatory drugs.
Fiorucci S; Mencarelli A; Distrutti E; Baldoni M; del Soldato P; Morelli A
J Immunol; 2004 Jul; 173(2):874-82. PubMed ID: 15240674
[TBL] [Abstract][Full Text] [Related]
18. Comparative effects of aspirin and NO-releasing aspirins on differentiation, maturation and function of human monocyte-derived dendritic cells in vitro.
Bufan B; Mojsilović S; Vucićević D; Vucević D; Vasilijić S; Balint B; Colić M
Int Immunopharmacol; 2009 Jul; 9(7-8):910-7. PubMed ID: 19341823
[TBL] [Abstract][Full Text] [Related]
19. Nitric oxide affects cisplatin cytotoxicity oppositely in A2780 and A2780-CDDP cells via the connexin32/gap junction.
Fan L; Zheng N; Peng F; Zhao Z; Fan D; Cai S; Tao L; Wang Q
Cancer Sci; 2020 Aug; 111(8):2779-2788. PubMed ID: 32342615
[TBL] [Abstract][Full Text] [Related]
20. Anti-thrombotic effects of a nitric oxide-releasing, gastric-sparing aspirin derivative.
Wallace JL; McKnight W; Del Soldato P; Baydoun AR; Cirino G
J Clin Invest; 1995 Dec; 96(6):2711-8. PubMed ID: 8675638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
